| Medical and Health Sciences | Lifetime | 772 | US 397 | 99.97 |
| Medical and Health Sciences | 2021-2025 | 260 | US 92 | 99.95 |
| Immunology and Allergy | Lifetime | 29 | US 17 | 99.48 |
| Medical Genetics | Lifetime | 70 | US 43 | 99.46 |
| Medical Physiology | Lifetime | 292 | US 167 | 99.53 |
| Rheumatology | Lifetime | 143 | US 63 | 99.43 |
| Public, Environmental and Occupational Health | Lifetime | 661 | US 336 | 99.08 |
| Dermatology | Lifetime | 220 | US 93 | 98.59 |
| Pulmonary and Respiratory Medicine | Lifetime | 886 | US 456 | 98.57 |
| Health, Toxicology and Mutagenesis | Lifetime | 567 | US 208 | 97.55 |
| Clinical Pharmacology | Lifetime | 981 | US 423 | 95.25 |
| Hematology | Lifetime | 833 | US 408 | 91.92 |
| Otolaryngology | Lifetime | 484 | US 230 | 89.06 |
| Sensory Systems | Lifetime | 484 | US 247 | 88.15 |
| Rheumatology | 2021-2025 | 12 | US 4 | 99.71 |
| Medical Genetics | 2021-2025 | 25 | US 14 | 99.42 |
| Medical Physiology | 2021-2025 | 125 | US 43 | 98.56 |
| Immunology and Allergy | 2021-2025 | 24 | US 12 | 98.85 |
| Pathology and Forensic Medicine | 2021-2025 | 201 | US 70 | 94.42 |
| Dermatology | 2021-2025 | 176 | US 55 | 93.65 |
| Immunology | 2021-2025 | 371 | US 134 | 89.91 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 673 | US 241 | 91.77 |
| Otolaryngology | 2021-2025 | 127 | US 47 | 90.24 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 6 | US 2 | 99.73 |
| Urticaria and Related Conditions | Lifetime | 3 | US 1 | 99.80 |
| Autoimmune Bullous Skin Diseases | Lifetime | 9 | US 5 | 99.77 |
| Allergic Rhinitis and Sensitization | Lifetime | 28 | US 12 | 99.81 |
| Occupational exposure and asthma | Lifetime | 9 | US 3 | 99.52 |
| Asthma and respiratory diseases | Lifetime | 72 | US 26 | 99.76 |
| Drug-Induced Adverse Reactions | Lifetime | 20 | US 7 | 99.30 |
| Mast cells and histamine | Lifetime | 38 | US 18 | 99.19 |
| Contact Dermatitis and Allergies | Lifetime | 41 | US 14 | 99.39 |
| Olfactory and Sensory Function Studies | Lifetime | 67 | US 30 | 98.99 |
| Indoor Air Quality and Microbial Exposure | Lifetime | 41 | US 16 | 98.97 |
| Respiratory and Cough-Related Research | Lifetime | 79 | US 30 | 99.43 |
| Vitamin K Research Studies | Lifetime | 25 | US 16 | 98.63 |
| Dermatology and Skin Diseases | Lifetime | 137 | US 47 | 99.20 |
| Food Allergy and Anaphylaxis Research | Lifetime | 85 | US 32 | 99.25 |
| Hemophilia Treatment and Research | Lifetime | 62 | US 25 | 98.85 |
| Pharmaceutical studies and practices | Lifetime | 221 | US 115 | 97.99 |
| Inhalation and Respiratory Drug Delivery | Lifetime | 204 | US 82 | 98.27 |
| Genital Health and Disease | Lifetime | 480 | US 212 | 96.18 |
| Sinusitis and nasal conditions | Lifetime | 452 | US 226 | 95.94 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 642 | US 245 | 89.60 |
| Nasal Surgery and Airway Studies | Lifetime | 909 | US 396 | 90.03 |
| Enzyme function and inhibition | Lifetime | 779 | US 376 | 89.26 |
| Chemical Safety and Risk Management | Lifetime | 552 | US 238 | 80.17 |
| Autoimmune Bullous Skin Diseases | 2021-2025 | 3 | US 1 | 99.81 |
| Urticaria and Related Conditions | 2021-2025 | 2 | US 1 | 99.78 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 3 | US 1 | 99.76 |
| Asthma and respiratory diseases | 2021-2025 | 28 | US 8 | 99.58 |
| Mast cells and histamine | 2021-2025 | 6 | US 3 | 99.15 |
| Allergic Rhinitis and Sensitization | 2021-2025 | 26 | US 8 | 99.48 |
| Dermatology and Skin Diseases | 2021-2025 | 91 | US 26 | 98.52 |
| Drug-Induced Adverse Reactions | 2021-2025 | 35 | US 11 | 97.02 |
| Respiratory and Cough-Related Research | 2021-2025 | 86 | US 20 | 96.99 |
| Sinusitis and nasal conditions | 2021-2025 | 90 | US 37 | 95.75 |
| Hemophilia Treatment and Research | 2021-2025 | 70 | US 19 | 95.98 |
| Vitamin K Research Studies | 2021-2025 | 37 | US 7 | 84.18 |
| Food Allergy and Anaphylaxis Research | 2021-2025 | 392 | US 110 | 90.24 |
| Pharmaceutical studies and practices | 2021-2025 | 406 | US 137 | 84.30 |
| Pediatric health and respiratory diseases | 2021-2025 | 398 | US 71 | 82.13 |
| Olfactory and Sensory Function Studies | 2021-2025 | 717 | US 156 | 80.66 |
| Nasal Surgery and Airway Studies | 2021-2025 | 368 | US 131 | 77.83 |
| Inhalation and Respiratory Drug Delivery | 2021-2025 | 708 | US 153 | 78.59 |
| Enzyme function and inhibition | 2021-2025 | 846 | US 46 | 37.42 |